Related Experiment Videos
Controlled release tablet formulation containing natural Δ(9)-tetrahydrocannabinol
Nagendra S Punyamurthula1, Tushar Hingorani1, Goutham Adelli1
1a Department of Pharmaceutics and Drug Delivery , School of Pharmacy, University of Mississippi, University , MS , USA ;
Drug Development and Industrial Pharmacy
|November 21, 2015
Summary
New oral tablet formulations of delta-9-tetrahydrocannabinol (THC) offer controlled release for managing chemotherapy-induced nausea and vomiting (CINV). These once-daily tablets improve patient compliance and CINV treatment.
Area of Science:
- Pharmacology
- Drug Delivery Systems
- Oncology Supportive Care
Background:
- Cannabinoids, including delta-9-tetrahydrocannabinol (THC), are utilized for chemotherapy-induced nausea and vomiting (CINV).
- Current capsule formulations require frequent dosing, leading to poor patient compliance.
- Development of sustained-release oral formulations is needed to improve CINV management.
Purpose of the Study:
- To develop and evaluate oral controlled-release tablet formulations of THC.
- To investigate the impact of lipid excipients (Precirol®, Compritol®) and diluents on THC release.
- To assess the feasibility of once-daily administration for improved CINV treatment.
Main Methods:
- Preparation of THC-loaded lipid matrices and blends using Precirol® and Compritol®.
- Evaluation of tablet characteristics and in vitro drug release profiles.
- Investigation of THC release in the presence of a lipase inhibitor (Pluronic® F68).
Main Results:
- A 24-hour zero-order THC release profile was achieved using a combination of Precirol® and Compritol® in the compression blend.
- The addition of Pluronic® F68 did not significantly alter in vitro THC release.
- Optimized tablets demonstrated chemical and physical stability over 3 months at 25°C/60% RH.
Conclusions:
- Oral controlled-release THC tablets can be successfully prepared using lipid excipients.
- These novel formulations enable once-daily administration, potentially enhancing patient compliance.
- The developed THC tablets show promise for improving the management of chemotherapy-induced nausea and vomiting.